Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2022 11:52 ET | Source: Biofrontera Inc.

Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022

WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will...
October 20, 2022 11:40 ET | Source: Biofrontera Inc.

Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
October 14, 2022 08:40 ET | Source: Biofrontera Inc.

Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan

WOBURN, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
September 29, 2022 10:04 ET | Source: Biofrontera Inc.

Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

WOBURN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
August 04, 2022 08:30 ET | Source: Biofrontera Inc.

Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022

WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will...
August 01, 2022 11:00 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH

Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduced Pain Intensity while Maintaining Efficacy WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI),...
May 19, 2022 09:48 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Closing of $9.4 Million Private Placement

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...
April 13, 2022 10:10 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®

Significantly Improves Manufacturing Efficiency, Quality Control and Supply Reliability WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical...
April 06, 2022 08:30 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022

WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today...